Core Viewpoint - Jiangsu Harbin Intelligent Robot Co., Ltd. has received a decision from the Shenzhen Stock Exchange to terminate its stock listing, which will subsequently transfer to the National Equities Exchange and Quotations for management in the delisting sector [2][3]. Group 1: Termination of Listing - The Shenzhen Stock Exchange has decided to terminate the listing of Jiangsu Harbin Intelligent Robot Co., Ltd.'s stock as of June 12, 2025 [2]. - Following the termination, the company's stock will be managed in the delisting sector, requiring the company to engage a qualified securities firm for share transfer services [3]. Group 2: Engagement of Sponsor Broker - Jiangsu Harbin Intelligent Robot Co., Ltd. has signed a stock transfer agreement with Great Wall Guorui Securities Co., Ltd. to act as its sponsor broker [3]. - The sponsor broker will handle the necessary procedures for share exit registration, re-confirmation, and registration settlement in the delisting sector [3]. Group 3: Company Information - Jiangsu Harbin Intelligent Robot Co., Ltd. is a limited liability company with state-owned control, established in February 1997, with a registered capital of 335 million yuan [4]. - The company is located in Xiamen and engages in various securities-related services, including brokerage, investment consulting, and asset management [4]. Group 4: Other Matters - Prior to the delisting, the company has disclosed relevant information through designated media, and further announcements regarding share confirmation and registration procedures will be made [4].

Core Viewpoint - Eason Technology Limited is currently not in compliance with NYSE American listing standards due to the failure to timely file its 2024 Form 20-F, which was due by May 15, 2025 [1][3]. Group 1: Compliance and Filing Status - The company received a notice from NYSE Regulation regarding its non-compliance with continued listing standards [1]. - The company is subject to a six-month Initial Cure Period until November 15, 2025, to rectify the Filing Delinquency [2]. - If the company fails to cure the delinquency within the Initial Cure Period, it may be granted an Additional Cure Period of up to six months, or face suspension and delisting procedures [2]. Group 2: Reasons for Filing Delay - The company cited delays in completing its financial statements for the period ended December 31, 2024, as the reason for not filing the 2024 Form 20-F on time [3]. - The company is making efforts to file the 2024 Form 20-F as soon as possible within the Initial Cure Period, but there is no assurance of regaining compliance [3]. Group 3: Impact on Trading - The delinquency notice does not have an immediate impact on the listing of the company's American Depositary Shares (ADSs), which will continue to be traded on NYSE American during the cure period [4]. Group 4: Company Overview - Eason Technology Limited is engaged in real estate operation management and investment, as well as digital technology security business in Hong Kong, China [5].

CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for ...

Group 1 - Since May, several companies including *ST Zhongcheng, *ST Renle, *ST Hengli, and *ST Gongzhi have announced receipt of termination of listing advance notice, indicating a trend of companies leaving the capital market [1][3] - As of May 12, 2025, a total of 10 companies have received termination of listing advance notices from the Shanghai and Shenzhen Stock Exchanges, with additional companies like *ST Puli and *ST Xulan also facing similar fates [1][3] - The new delisting regulations have been implemented, leading to the first annual report season under these rules, resulting in multiple companies being warned of delisting risks and several directly delisted [5] Group 2 - *ST Renle reported a net asset of -387 million yuan for 2023 and -404 million yuan for 2024, triggering termination of listing due to financial report issues [3] - *ST Hengli's 2023 net profit was negative, and its revenue was below 100 million yuan, leading to a delisting risk warning [3][4] - *ST Zhongcheng's 2023 net asset was also negative, and its 2024 financial report received a qualified opinion, resulting in a proposed termination of listing [3][4] Group 3 - A total of 9 companies have completed delisting in 2025, with reasons ranging from continuous low stock prices to major violations [6][7] - The companies that have delisted include *ST Meixun, Haitong Securities, and *ST Boxin, among others, with various reasons for their delisting [7][8] - The trend indicates a significant number of companies facing financial difficulties and regulatory challenges, leading to increased scrutiny and potential delisting [10] Group 4 - The Beijing Stock Exchange may see its first delisted company, with Guandao Digital and Yun Chuang Data facing delisting risks due to audit issues [9][10] - Both companies have received audit opinions that could lead to termination of listing if they continue to meet financial delisting criteria in 2025 [10] - A total of 96 companies in the A-share market have been warned of delisting risks due to various financial issues, indicating a broader trend of financial instability among listed companies [10]

Core Viewpoint - Vincerx Pharma, Inc. is set to delist its common stock from Nasdaq due to non-compliance with listing rules, with trading suspended and plans for liquidation announced [2][3][4]. Group 1: Delisting and Trading Suspension - Vincerx received a delisting notice from Nasdaq on April 14, 2025, due to its common stock closing bid price being below the minimum requirement of $1.00 per share for 30 consecutive business days [2]. - Trading of Vincerx's common stock will be suspended at the opening of business on April 23, 2025, and the company intends to file a Form 25 Notification of Delisting with the SEC around April 28, 2025 [1][2]. - An inadvertent suspension of trading occurred on April 16, 2025, but trading will resume on April 21, 2025, until April 22, 2025 [4]. Group 2: Company Actions and Future Plans - The board of directors has decided to dissolve, liquidate, and wind up the company's affairs, distributing any remaining assets to stockholders after settling debts [3]. - Vincerx does not plan to appeal Nasdaq's determination and will not seek to list its common stock on another exchange [3]. - Following the effectiveness of Form 25, Vincerx will file a Form 15 to deregister with the SEC [4]. Group 3: Company Background - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, with a research facility in Monheim, Germany [5].

编者按 | 常态化退市机制是保障资本市场良性运行的关键，为深化投资者对退市板块的理解与认 | | --- | | 0 2 识，在2 4年金融宣传月期间，我们特推出"退市板块知识宝典"系列图文，从上市公司退市 | | 后相关安排、退市公司股票转让规则、退市可转债管理等方面，向投资者普及上市公司退市 | | 后的基础知识。本期介绍退市公股票恢复转让和终止转让的情形，快来一起了解一下吧！ | ...